论文部分内容阅读
目的观察门冬氨酸鸟氨酸(OA)治疗肝性脑病的临床疗效。方法以90例确诊肝硬化、肝功能C级伴发肝性脑病的患者作为研究对象,随机后分为低剂量治疗组(LT)、高剂量治疗组(HT)和对照组(C/精氨酸治疗组):于治疗前后测定门体性脑病指数(PSEI),对临床疗效进行评价。结果治疗7d末PSEI评分疗效检验结果显示,高剂量组、低剂量组,对照组都有PSEI的下降.治疗总有效率分别为80.00%、56.67%和36.67%,三组间比较均有统计学差别。结论门冬氨酸鸟氨酸可显著降低C型肝性脑病的门体脑病指数具有一定的保肝、退黄作用.
Objective To observe the clinical efficacy of ornithine ornithine (OA) in the treatment of hepatic encephalopathy. Methods Ninety patients with cirrhosis and grade C hepatic encephalopathy were randomly divided into two groups: low dose treatment group (LT), high dose treatment group (HT) and control group (C / Acid treatment group): before and after treatment for the determination of portal encephalopathy index (PSEI), the clinical efficacy evaluation. Results The therapeutic effect of PSEI score at the end of 7th day of treatment showed that the decrease of PSEI was found in high dose group, low dose group and control group.The total effective rates were 80.00%, 56.67% and 36.67%, respectively, with statistically significant differences among the three groups difference. CONCLUSION Aspartate ornithine can significantly reduce the portal encephalopathy index of C-type hepatic encephalopathy with certain hepatoprotective and dementia effects.